Status:
TERMINATED
Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Growth Disorders
Eligibility:
All Genders
Up to 18 years
Brief Summary
Assessment of long-term effectiveness of ZOMACTON in treatment of Growth Hormone Deficiency or growth retardation due to Ullrich-Turner Syndrome and assessment of compliance and adherence, optionally ...
Eligibility Criteria
Inclusion
- Pediatric patients (\< 18 years) with growth hormone deficiency or growth retardation due to Ullrich-Turner-Syndrome
- Patients already receiving or who have been prescribed Zomacton® de novo according to its German label; the decision to prescribe Zomacton® was made independently from participation and prior to enrollment in this study.
- Patient and their parents (or legal representatives) who are willing and able to provide signed informed consent for use of their personal data.
Exclusion
- Participation in an interventional clinical study within the last 30 days prior to baseline visit or during the follow-up period
Key Trial Info
Start Date :
May 14 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2018
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT03274973
Start Date
May 14 2018
End Date
October 31 2018
Last Update
December 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinik fuer Allgemeine Paediatrie der Christian-Albrechts-Universitaet zu Kiel (there might be other sites in this country)
Kiel, Germany, 24105